Skip to main content

Market Overview

UPDATE: CRT Capital Upgrades Akorn


CRT Capital upgraded Akorn, Inc. (NASDAQ: AKRX) from Fair Value to Buy with a $46 price target.

Analyst Tim Chiang believed “the recent sell off in AKRX shares post 3Q results creates a potential buying opportunity, based on our view that the Company will benefit from solid pricing trends in products like topical Clobetasol propionate (a commonly prescribed corticosteroid for the treatment of various skin conditions like eczema).”

Chiang estimated 2014 to 2016 “Clobetasol sales of $39M, $85M, and $102M, respectively. Our analysis of this suggest that recent price hikes by a competitor, Taro, could lead to higher sales and profits for all of the major players in this market, with Akorn currently the No.2 player by market share. We forecast Clobetasol’s gross margins above 90 percent throughout the F’14 – F’20 period.”

“Clobetasol represents a large market, counting over 6 million retail prescriptions in the US in 2013. The majority of those, about 84 percent of the prescription count (and likely 50 percent of the total amount spent) are for the cream, ointment and topical solution presentations,” according to the analyst report.

Chiang concluded that “AKRX shares trade at ~22x our 15 EPS forecast of $1.68, a ~30 percent premium to its peer group. While AKRX shares do trade at a premium, we believe Akorn has a 14-18 CAGR of ~30 percent, which is higher than its peers.”

Akorn recently traded at $38.33, up 1.73 percent.

Latest Ratings for AKRX

Sep 2019SunTrust Robinson HumphreyMaintainsHold
Mar 2019SunTrust Robinson HumphreyInitiates Coverage OnHold
Oct 2018PiperJaffrayUpgradesNeutralOverweight

View More Analyst Ratings for AKRX
View the Latest Analyst Ratings


Related Articles (AKRX)

View Comments and Join the Discussion!

Posted-In: CRT Tim ChiangAnalyst Color Upgrades Price Target Analyst Ratings

Latest Ratings

ETCredit SuisseMaintains13.0
IFRXCredit SuisseMaintains2.8
METCredit SuisseMaintains68.0
FLXNCredit SuisseMaintains14.0
ENPHCapital OneInitiates Coverage On175.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at